MEDI 3726

Drug Profile

MEDI 3726

Alternative Names: ADCT 401; MEDI3726

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator ADC Therapeutics
  • Developer ADC Therapeutics; MedImmune
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 06 Jan 2017 Phase-I clinical trials in Prostate cancer (Metastatic disease; Second line therapy or greater) in USA (NCT02991911)
  • 18 May 2014 Preclinical trials in Prostate cancer in United Kingdom (Parenteral)
  • 15 Oct 2013 Preclinical trials in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top